Whitening composition containing anithiactin A as an active ingredient and a method for producing said anithiactin A

Whitening ingredient based on the natural product anithiactin A that inhibits melanin production

This technology is a composition for whitening and improving hyperpigmentation that uses anithiactin A, or its salts, hydrates, or solvates isolated from natural sources, as an active ingredient. It inhibits melanin production to prevent or alleviate pigmentation such as melasma, freckles, and solar lentigo.

Existing whitening ingredients like kojic acid, arbutin, hydroquinone, and vitamin C derivatives often have weak efficacy or associated cytotoxicity, leading to a lack of ingredients that are both safe and effective. While the existence of anithiactin A was known, it had not been utilized as an ingredient because its whitening efficacy had not been studied.

This technology offers a naturally derived substance that effectively inhibits melanin production even at low concentrations of 1–100 ppm, reducing concerns about the toxicity of existing ingredients. It can be applied to functional whitening cosmetics, topical treatments for melasma and age spots, and inner-beauty products for skin tone improvement, providing a differentiated candidate for ingredient companies seeking new whitening actives.

‍

‍

Key Features:

• Whitening cosmetic composition containing anithiactin A or its pharmaceutically acceptable salts, hydrates, or solvates as an active ingredient
• Composition that inhibits skin pigmentation or melanin production and contains 1 ppm to 100 ppm of anithiactin A
• Pharmaceutical composition for the prevention or treatment of hyperpigmentation disorders such as freckles, melasma, post-inflammatory hyperpigmentation, solar lentigo, café-au-lait spots, and age spots
• Food composition that contains anithiactin A as an active ingredient to prevent or improve hyperpigmentation disorders by inhibiting melanin production

‍

This invention was developed with support from the Ministry of Health and Welfare for the development of Korean-style ex vivo skin models and integrated animal-alternative efficacy evaluation technology based on 3D skin tissue.

‍